Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3289997rdf:typepubmed:Citationlld:pubmed
pubmed-article:3289997lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:3289997lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3289997lifeskim:mentionsumls-concept:C0020663lld:lifeskim
pubmed-article:3289997lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:3289997lifeskim:mentionsumls-concept:C0027893lld:lifeskim
pubmed-article:3289997lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:3289997pubmed:issue6lld:pubmed
pubmed-article:3289997pubmed:dateCreated1988-8-4lld:pubmed
pubmed-article:3289997pubmed:abstractTextCentral and lateral hypothalamic concentrations of 10 regulatory peptides were measured by radioimmunoassay in streptozocin-induced diabetic (STZ-D) and matched control rats between 1 day and 14 wk after diabetes induction. After 2 wk, both central and lateral hypothalamic neuropeptide Y (NPY) concentrations in STZ-D rats were consistently higher than those found in control rats, with significant 30-50% increases at 4 wk in the central hypothalamus, and at 6 and 14 wk in both central and lateral hypothalamus. Immunocytochemical studies in 4- and 6-wk STZ-D animals showed the appearance of intensely NPY-positive swollen cell bodies in the supraoptic nucleus and a subjective increase in NPY staining of medial hypothalamic nerve fibers. Central hypothalamic concentrations of three other peptides were significantly greater in STZ-D animals than those in control animals at single points (neurotensin, 1 day; calcitonin gene-related peptide, 2 wk; neurokinin, 4 wk). Hypothalamic concentrations of the other six peptides examined (bombesin, galanin, neuromedin B, substance P, somatostatin, and vasoactive intestinal peptide) did not differ significantly between STZ-D and control groups at any time. However, galanin immunostaining in the supraoptic and magnocellular paraventricular nuclei was strikingly concentrated in a reduced number of distended cell bodies. Hypothalamic peptide changes in STZ-D could be related to metabolic disturbance, changes in energy and water balance, altered pituitary function, or other factors. Persistently elevated concentrations of NPY, a very potent central stimulant of eating and drinking, may mediate the hyperphagia and polydipsia characteristic of STZ-D.lld:pubmed
pubmed-article:3289997pubmed:languageenglld:pubmed
pubmed-article:3289997pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3289997pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3289997pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3289997pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3289997pubmed:statusMEDLINElld:pubmed
pubmed-article:3289997pubmed:monthJunlld:pubmed
pubmed-article:3289997pubmed:issn0012-1797lld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:LeeY CYClld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:PolakJ MJMlld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:BloomS RSRlld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:WilliamsGGlld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:BurrinJ MJMlld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:GhateiM AMAlld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:CardosoHHlld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:GillJ SJSlld:pubmed
pubmed-article:3289997pubmed:authorpubmed-author:SteelJ HJHlld:pubmed
pubmed-article:3289997pubmed:issnTypePrintlld:pubmed
pubmed-article:3289997pubmed:volume37lld:pubmed
pubmed-article:3289997pubmed:ownerNLMlld:pubmed
pubmed-article:3289997pubmed:authorsCompleteYlld:pubmed
pubmed-article:3289997pubmed:pagination763-72lld:pubmed
pubmed-article:3289997pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:meshHeadingpubmed-meshheading:3289997-...lld:pubmed
pubmed-article:3289997pubmed:year1988lld:pubmed
pubmed-article:3289997pubmed:articleTitleIncreased hypothalamic neuropeptide Y concentrations in diabetic rat.lld:pubmed
pubmed-article:3289997pubmed:affiliationFrancis Fraser Laboratories, Department of Medicine, Royal Postgraduate Medical School, London, United Kingdom.lld:pubmed
pubmed-article:3289997pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3289997pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3289997lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3289997lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3289997lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3289997lld:pubmed